Compare HSBC & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HSBC | GKOS |
|---|---|---|
| Founded | 1865 | 1998 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.5B | 5.4B |
| IPO Year | N/A | 2015 |
| Metric | HSBC | GKOS |
|---|---|---|
| Price | $74.94 | $109.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 13 |
| Target Price | N/A | ★ $123.62 |
| AVG Volume (30 Days) | ★ 1.7M | 846.3K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.93 | N/A |
| Revenue | ★ $57,976,000,000.00 | $469,820,000.00 |
| Revenue This Year | $12.50 | $31.15 |
| Revenue Next Year | $2.06 | $24.15 |
| P/E Ratio | $80.68 | ★ N/A |
| Revenue Growth | 0.01 | ★ 30.38 |
| 52 Week Low | $45.66 | $73.16 |
| 52 Week High | $75.44 | $163.71 |
| Indicator | HSBC | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 67.11 | 70.89 |
| Support Level | $70.77 | $105.88 |
| Resistance Level | $72.24 | $110.87 |
| Average True Range (ATR) | 0.67 | 3.39 |
| MACD | 0.39 | -0.04 |
| Stochastic Oscillator | 91.48 | 80.77 |
Established in 1865 in Hong Kong, London-based HSBC is one of the largest banks in the world, with assets of USD 3 trillion and 40 million customers worldwide. It operates in more than 50 countries with more than 200,000 full-time staff. The United Kingdom and Hong Kong are its two largest markets. The bank offers retail, commercial and institutional banking, global banking and markets, wealth management, and private banking.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.